Subcutaneous daratumumab for the treatment of multiple myeloma

Abstract

Subcutaneous daratumumab is a human immunoglobulin G1 kappa monoclonal antibody targeting CD38. Currently, it is FDA-registered to treat multiple myeloma (MM) as both newly diagnosed MM and relapsed refractory MM. This treatment aims to decrease drug administration duration and reduce the incidence of high infusion-related reactions (IRRs) when administered intravenously daratumamab (IV-daratumamab). SC-daratumumab has a significantly shorter period of administration (SC vs. IV: median 1st dose 3–5 minutes vs. 7 hours), lower volume of administration (SC vs. IV: median 15 mL vs. 500–1000 mL), and lower risk of IRRs (SC vs. IV: median 1thdose less than 10% vs. 50%). In conclusion, SC-daratumamab is non-inferior to IV-daratumamab.